(0.09%) 5 474.06 points
(0.10%) 39 152 points
(0.40%) 17 789 points
(-0.21%) $80.66
(-3.66%) $2.66
(-0.77%) $2 312.90
(0.20%) $28.93
(3.49%) $1 020.80
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company\'s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach...
Stats | |
---|---|
今日成交量 | 1.79M |
平均成交量 | 725 973 |
市值 | 0.00 |
EPS | $-0.550 ( Q3 | 2022-11-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.69 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.438 (3.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-30 | Walker Paul Edward | Sell | 4 294 207 | Common Stock |
2022-11-30 | Sonsini Peter W. | Sell | 4 294 207 | Common Stock |
2022-11-30 | Sandell Scott D | Sell | 4 294 207 | Common Stock |
2022-12-01 | Mathers Edward T | Sell | 16 000 | Stock Option (right to buy) |
2022-11-30 | Makhzoumi Mohamad | Sell | 4 294 207 | Common Stock |
INSIDER POWER |
---|
-17.62 |
Last 97 transactions |
Buy: 48 602 836 | Sell: 208 882 585 |
音量 相关性
Akouos, Inc. 相关性 - 货币/商品
Akouos, Inc. 财务报表
Annual | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.94 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.94 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.77 |
FY | 2019 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.65 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Akouos, Inc.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company\'s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。